A Study of the Effect of Diltiazem on the Plasma Levels of Nemtabrutinib (MK-1026-022)

Sex: All

Ages: 18 Years – 55 Years

Healthy volunteers: Yes

Phase: PHASE1

Enrollment: 26

Sponsor: Merck Sharp & Dohme LLC

Summary

The goal of the study is to learn what happens to levels of nemtabrutinib (MK-1026) in a healthy person's body over time. Researchers will compare what happens to nemtabrutinib in the body when it is given with or without another medicine called diltiazem.

Eligibility Criteria

Inclusion Criteria: * Be in good health * BMI between 18.5 and 32 kg/m2, inclusive Exclusion Criteria: * History of clinically significant endocrine, gastrointestinal, cardiovascular, hematological (history of a bleeding disorder, abnormal bleeding or a hereditary or acquired coagulation or platelet disorder), hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke, intercranial hemorrhage, and chronic seizures) abnormalities or diseases * History of cancer (malignancy)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07232589). StuddyBuddy aggregates publicly available trial information.